Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 2/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409226 | 1.00 | CTSK (0.45) | CTSKCA1CA2CA7TDP1 | |
| SCHEMBL15739550 | 0.82 | TDP1 (0.38) | CTSKCA1CA2CA7TDP1 | |
| SCHEMBL31430383 | 0.80 | CTSK (0.41) | CTSKCA1CA2CA7TDP1 | |
| SCHEMBL19193058 | 0.80 | CTSK (0.39) | CTSKCA1CA2CA7TDP1 | |
| SCHEMBL20748761 | 0.79 | CTSK (0.38) | CTSKCA1CA2CA7TDP1 | |
| SCHEMBL28901137 | 0.79 | CTSK (0.38) | CTSKCA1CA2CA7TDP1 | |
| SCHEMBL14488940 | 0.78 | HCAR2 (0.38) | — | |
| SCHEMBL2926580 | 0.77 | TSHR (0.37) | CTSKCA1CA2CA7TDP1 | |
| SCHEMBL101218 | 0.77 | DGAT1 (0.46) | CTSKCA1CA2CA7TDP1 | |
| SCHEMBL20748762 | 0.76 | CTSK (0.36) | CTSKCA1CA2CA7TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210188777-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | ST JUDE CHILDRENS RES HOSPITAL (US) | 2021-06-24 | — | — | US | disclosed |
| US-11028051-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2018111805-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2018-06-21 | — | — | WO | disclosed |
| EP-2496558-B1 | TETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-8580957-B2 | Thetrahydroquinolines derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580957-B2 | Thetrahydroquinolines derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011054848-A1 | THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054841-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-7232923-B2 | Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines | IMPERIAL INNOVATIONS LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-20060183933-A1 | Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines | IMPERIAL COLLEGE INNOVATION LIMITED (GB) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | BRD4, BRDT, BRPF3 | CTSK 2064/4885CA1 4010/4885CA2 2622/4885 |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | ABCB1, CYP3A7, UGT2B7 | CTSK 1850/4885CA1 4700/4885CA2 3451/4885 |
| US-11028051-B2 | Tetrahydroquinoline-based bromodomain inhibitors | BRDT, BRD4, BRD3 | CTSK 3067/4885CA1 3569/4885CA2 4321/4885 |
| US-20210188777-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | BRDT, BRD4, BRD3 | CTSK 3067/4885CA1 3569/4885CA2 4321/4885 |
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | BRDT, BRD4, BRD3 | CTSK 3067/4885CA1 3569/4885CA2 4321/4885 |
| US-20060183933-A1 | Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines | ALKBH3, HNMT, ALKBH1 | CTSK 2262/4885CA1 684/4885CA2 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.